Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
MENLO PARK, Calif., April 20, 2018 -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its First Quarter 2018 Financial Results on Wednesday, May 2, 2018, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: May 2, 2018
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Conference ID: 2187939
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Contact: Pacific Biosciences
Trevin Rard
650.521.8450
[email protected]
